Fig. 4: NPD8790 shows distinct bioactivity from that of existing benzimidazole anthelmintics.
From: Identification of a family of species-selective complex I inhibitors as potential anthelmintics
a Chemical structures of NPD8790 and the commercial benzimidazole anthelmintic, fenbendazole. b Dose response of fenbendazole and NPD8790 in two assays of C. elegans viability for six different C. elegans strains: N2, wild type; ECA882, deletion (ben-1); ECA917, F200Y (ben-1); ECA1075, F167Y (ben-1); ECA1080, E198A (ben-1); CB3474, G104D (ben-1). The color-coded scale denotes the phenotypic outcome of drug treatment (e.g., motility or viability) relative to DMSO controls; white/pale-yellow indicates C. elegans growth and viability similar to DMSO controls and red indicates C. elegans death and arrested development. c Dose-response curves of four commercial benzimidazole anthelmintics and NPD8790 against the in vitro complex I activity from wild-type C. elegans (N2) mitochondria. IC50 values estimated from fitted curves are displayed for each compound; “ND” indicates an IC50 values was not determined. d Dose-response curves of NPD8790 against the in vitro activity of complex I from wild-type (N2) mitochondria, and mitochondria from C. elegans benzimidazole-resistant mutant strains: ECA882, ECA917, ECA1075, ECA1080 and CB3474. NPD8790 IC50 values estimated from fitted curves are displayed for each strain. All data are the mean of at least three biological replicates; error bars in mitochondrial assays represent SEM.
